Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest To Test Alzheimer’s Drug Neramexane As Monotherapy in Phase II/III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The NMDA receptor agonist failed to show efficacy as a combination therapy with acetylcholinesterase inhibitors in pivotal trial for moderate-to-severe disease, Forest says.

You may also be interested in...



Desmoteplase Approval For Stroke Expected In 2009, Forest Says

Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.

Desmoteplase Approval For Stroke Expected In 2009, Forest Says

Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.

Forest Namenda Has 10% Off-Label Use Based On Initial Launch Data

The company said 70% of use was in moderate Alzehimer's cases and 20% was in severe cases. The company expects to file an sNDA for a mild-to-moderate indication by "late this summer."

Topics

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel